Methods of producing anamorelin hydrochloride having controlled chloride content
US-2016235804-A1 · Aug 18, 2016 · US
US9956261B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9956261-B2 |
| Application number | US-201615135107-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 21, 2016 |
| Priority date | Apr 20, 2012 |
| Publication date | May 1, 2018 |
| Grant date | May 1, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
Opening claim text (preview).
The invention claimed is: 1. Anamorelin monohydrochloride comprising less than 3% total impurities selected from by-products, contaminants, and degradation products. 2. The anamorelin monohydrochloride of claim 1 , comprising less than 2% total impurities selected from by-products, contaminants, and degradation products. 3. The anamorelin monohydrochloride of claim 1 , comprising less than 1% total impurities selected from by-products, contaminants, and degradation products. 4. The anamorelin monohydrochloride of claim 1 , comprising less than 5% water. 5. The anamorelin monohydrochloride of claim 1 , comprising less than 3% water. 6. The anamorelin monohydrochloride of claim 1 , comprising less than 2% water. 7. The anamorelin monohydrochloride of claim 1 in an isolated state. 8. The anamorelin monohydrochloride of claim 1 in combination with one or more pharmaceutically acceptable excipients. 9. The anamorelin monohydrochloride of claim 1 in combination with one or more pharmaceutically acceptable excipients in the form a tablet or capsule or pellets or granules or powders. 10. The anamorelin monohydrochloride of claim 1 having a solubility in water greater than 100 mg/mL. 11. The anamorelin monohydrochloride of claim 1 having a solubility in water greater than 333 mg/mL. 12. The anamorelin monohydrochloride of claim 1 having a stability defined by a percentage increase in impurities of no more than 114% when stored at 25° C. and a relative humidity of 60% for two years. 13. The anamorelin monohydrochloride of claim 1 having a stability defined by a percentage increase in impurities of no more than 48% when stored at 25° C. and a relative humidity of 60% for two years. 14. The anamorelin monohydrochloride of claim 1 having a chloride content of from 5.6 to 6.3%. 15. The anamorelin monohydrochloride of claim 1 having a residual solvent concentration less than 5000 ppm, wherein the residual solvent concentration excludes water. 16. The anamorelin monohydrochloride of claim 1 , wherein the anamorelin monohydrochloride has a solubility in water greater than 333 mg/mL, and a stability defined by a percentage increase in impurities of no more than 114% when stored at 25° C. and a relative humidity of 60% for two years. 17. The anamorelin monohydrochloride of claim 1 having a chloride content of from 5.6 to 6.2% and a residual solvent concentration excluding water less than 5000 ppm, a solubility in water greater than 333 mg/mL, and a stability defined by a percentage increase in impurities of no more than 114% when stored at 25° C. and a relative humidity of 60% for two years. 18. Anamorelin monohydrochloride comprising: a) less than 3% total impurities selected from by-products, contaminants, and degradation products; b) a residual solvent concentration excluding water of less than 5000 ppm; and c) a chloride content of from 5.6 to 6.2%.
Anorexiants; Antiobesity agents · CPC title
the side chain containing 2 to 4 carbon atoms · CPC title
Dipeptides · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.